AMPH
Amphastar Pharmaceuticals Inc.
$25.50
+$0.84(+3.41%)
69
Overall
80
Value
66
Tech
63
Quality
Market Cap
$1.29B
Volume
552.33K
52W Range
$20.39 - $53.96
Target Price
$32.50
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $251.5M | $255.2M | $240.2M | $294.7M | $322.4M | $349.8M | $437.8M | $499.0M | $644.4M | $732.0M | ||
| Total Revenue | $251.5M | $255.2M | $240.2M | $294.7M | $322.4M | $349.8M | $437.8M | $499.0M | $644.4M | $732.0M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-174.2M | $-151.0M | $-149.7M | $-187.7M | $9.4M | $13.9M | $24.6M | $250.1M | $293.3M | $358.1M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $77.3M | $104.2M | $90.5M | $107.0M | $131.9M | $143.3M | $199.7M | $248.9M | $351.1M | $373.9M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-84.2M | $-88.5M | $-91.8M | $-115.6M | $132.0M | $132.4M | $129.9M | $141.4M | $154.1M | $168.4M | ||
| Research & Development | $37.3M | $41.2M | $43.5M | $57.6M | $68.9M | $67.2M | $60.9M | $74.8M | $73.7M | $73.9M | ||
| Research Expense | $37.3M | $41.2M | $43.5M | $57.6M | $68.9M | $67.2M | $60.9M | $74.8M | $73.7M | $73.9M | ||
| Selling, General & Administrative | $47.0M | $47.3M | $50.9M | $58.0M | $63.1M | $65.2M | $68.9M | $66.6M | $80.4M | $94.5M | ||
| Selling & Marketing Expenses | $5.5M | $5.5M | $6.5M | $8.2M | $12.8M | $14.8M | $17.5M | $21.5M | $28.9M | $37.8M | ||
| General & Administrative Expenses | $41.5M | $41.8M | $44.5M | $49.9M | $50.3M | $50.4M | $51.4M | $45.1M | $51.5M | $56.7M | ||
| Salaries & Wages | $-12.8M | $-15.1M | $-17.1M | $-16.7M | $200.0K | $200.0K | $-18.7M | -- | $20.2M | $24.4M | ||
| Depreciation & Amortization | $-11.3M | $-12.0M | $-13.0M | $-14.5M | $17.1M | $20.5M | $22.2M | $23.8M | $25.2M | $28.2M | ||
| Depreciation & Amortization | $-11.3M | $-12.0M | $-13.0M | $-14.5M | $17.1M | $20.5M | $22.2M | -- | -- | -- | ||
| Amortization | $-1.9M | $-2.5M | $-2.9M | $-2.0M | $4.0M | $4.3M | $3.7M | $3.6M | $24.2M | $31.1M | ||
| Other Operating Expenses | $-84.2M | $-88.5M | $-91.8M | $-115.6M | $-1.4M | $-1.8M | $-1.8M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-6.9M | $15.7M | $-3.9M | $-8.6M | $-39.0K | $11.0M | $69.9M | $107.5M | $197.0M | $205.4M | ||
| EBITDA | $3.9M | $30.5M | $17.9M | $6.8M | $81.5M | $30.2M | $111.6M | $145.4M | $249.7M | $272.5M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $987.0K | $1.0M | $826.0K | $243.0K | $119.0K | $374.0K | $885.0K | $1.8M | $27.2M | $30.3M | ||
| Intinc | $315.0K | $270.0K | $425.0K | $456.0K | $997.0K | $642.0K | $601.0K | $1.3M | $5.5M | $10.6M | ||
| Net Non-Operating Interest Income/Expense | $-672.0K | $-754.0K | $-401.0K | $213.0K | $878.0K | $268.0K | $-284.0K | $-525.0K | $-21.7M | $-19.7M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | -- | $13.6M | -- | -- | -- | ||
| Other Income/Expense | $2.8M | $-8.0K | $-5.6M | $1.5M | $131.0M | $6.6M | $-14.3M | $9.1M | $5.9M | $-3.5M | ||
| Other Special Charges | $-2.8M | $8.0K | $2.9M | $-1.5M | $59.4M | $-6.6M | $14.5M | $9.1M | $-3.9M | $4.1M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | -- | -- | -- | -- | $-374.0K | -- | -- | -- | ||
| Other Impairment Of Capital Assets | $206.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-9.4M | $16.0M | $2.1M | $-9.7M | $60.3M | $5.0M | $323.1M | $116.7M | $196.5M | $219.5M | ||
| Pre-Tax Income | $-10.4M | $14.9M | $1.2M | $-9.9M | $60.2M | $4.6M | $84.1M | $116.0M | $171.4M | $189.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-7.6M | $4.4M | $-2.4M | $-3.3M | $13.7M | $3.5M | $20.6M | $23.5M | $31.8M | $29.7M | ||
| NET INCOME | ||||||||||||
| Net Income | $-2.8M | $10.5M | $3.6M | $-5.7M | $48.9M | $1.4M | $62.1M | $91.4M | $137.5M | $159.5M | ||
| Net Income (Continuing Operations) | $-2.8M | $10.5M | $3.6M | $-5.7M | $48.9M | $1.4M | $62.1M | $91.4M | $137.5M | $159.5M | ||
| Net Income (Discontinued Operations) | $-2.8M | $10.5M | $3.6M | $-5.7M | $48.9M | $1.4M | $62.1M | $91.4M | $137.5M | $159.5M | ||
| Net Income (Common Stockholders) | $-2.8M | $10.5M | $3.6M | $-5.7M | $48.9M | $1.4M | $62.1M | $91.4M | $137.5M | $159.5M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $187.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-258.4M | $-239.5M | $-241.4M | $-303.3M | $141.4M | $146.3M | $154.5M | $391.5M | $447.4M | $526.5M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $45.0M | $45.4M | $46.1M | $46.4M | $47.0M | $47.0M | $47.8M | $48.6M | $48.3M | $48.4M | ||
| Average Shares Outstanding (Diluted) | $45.0M | $47.5M | $48.4M | $46.4M | $49.9M | $49.1M | $49.8M | $52.4M | $53.0M | $52.1M | ||
| Shares Outstanding | $44.9M | $45.9M | $46.4M | $46.8M | $46.2M | $47.4M | $48.1M | $47.9M | $48.1M | $95.3M | ||
| Basic EPS | $-0.06 | $0.23 | $0.08 | $-0.12 | $1.04 | $0.03 | $1.3 | $1.88 | $2.85 | $3.29 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $1.88 | $2.85 | $3.29 | ||
| Diluted EPS | $-0.06 | $0.22 | $0.08 | $-0.12 | $0.98 | $0.03 | $1.25 | $1.74 | $2.6 | $3.06 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $1.74 | $2.6 | $3.06 | ||
| OTHER METRICS | ||||||||||||
| Allowances For Construction | -- | -- | -- | -- | $190.4M | -- | -- | -- | -- | -- | ||
| Earnings from equity interest | -- | -- | -- | -- | -- | -- | $-208.0K | $-1.2M | $-2.0M | $-573.0K | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | -- | -- | $-208.0K | $-1.2M | $-2.0M | $-573.0K | ||
| Gain On Sale Of P P E | -- | -- | $2.6M | -- | -- | -- | -- | -- | -- | -- | ||
| Interest Expense Operating | -- | -- | -- | -- | -- | -- | $238.0M | -- | -- | -- | ||
| Minority Interests | -- | -- | -- | $922.0K | $2.4M | $306.0K | $-1.2M | -- | -- | -- | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | -- | -- | $374.0K | -- | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | -- | -- | -- | -- | $374.0K | -- | -- | -- | ||
| Other Gand A | $41.5M | $41.8M | $44.5M | $49.9M | $50.3M | $50.4M | $51.4M | $45.1M | $51.5M | $56.7M | ||
| Rent And Landing Fees | $41.5M | $41.8M | $44.5M | $49.9M | $50.3M | $50.4M | $51.4M | -- | -- | -- | ||
| Selling Expense | $5.5M | $5.5M | $6.5M | $8.2M | $12.8M | $14.8M | $17.5M | -- | -- | -- | ||
| Write Down | -- | -- | -- | -- | -- | -- | $374.0K | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AMPH | $25.50 | +3.4% | 552.33K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Amphastar Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW